Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Research Report - Global Forecast till 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Market Scenario

The Global IPF Treatment Market is expected to register a CAGR of 12.3% during the forecast period of 2019 to 2025 with a market value of USD 2237 million in 2018.

IPF is a lung disease which causes the tissue in your lungs to become stiff. The global IPF treatment market is driven by factors such as increasing cases of IPF and growing demand for minimally invasive procedures to diagnose and treat different chronic diseases. Additionally, rising prevalence rates of lung diseases coupled with increasing geriatric population is anticipated to fuel the market growth. For instance, according to the Office for National Statistics in 2017, approximately 18% and 2.4% of the total UK population was aged over 65 years and 85 years, respectively. On the other hand, the high cost of surgery is projected to hamper the growth of the market during the assessment period.

Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market. For instance, in April 2018, Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute entered into a research collaboration to discover and develop potential new therapies for fibrotic diseases.

Major Key Players

Some of the key players in the global IPF treatment market are Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibrogen, Inc., Cipla, Merck & Co., Inc., Prometic Life Sciences Inc., and others.

Intended Audience

- Research and development (r&d) companies
- Medical device companies
- Government research institutes
- Academic institutes and universities
- Venture capitalists

Market Segmentation

The global IPF treatment market has been segmented based on treatment and region.

The market, based on treatment, has been bifurcated into drug class, oxygen therapy, lung transplant, and others. The drug class segment is expected to hold a major share in the market due to the wider preferability and increasing adoption of the drugs for the treatment of IPF. The oxygen therapy segment is anticipated to be the fastest growing due to the rising inclination of medical professionals towards this therapy for the treatment of IPF.

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The IPF treatment market in the Americas has further been branched into North
America and Latin America, with the North American market divided into the US and Canada. The European IPF treatment market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The IPF treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The IPF treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Global IPF Treatment Market Share by Region, 2018 (%)

Regional Market Summary

The market in the Americas is expected to dominate the global IPF treatment market due to the increasing per capita healthcare expenditure and the high adoption of new technology in the region. High cases of pulmonary and cystic fibrosis in the US and Canada is expected to drive the market growth. Furthermore, increasing expenses in research by healthcare bodies is expected to fuel the growth of the market in this region.

The market in Europe showed a considerable amount of growth. This can be attributed to the presence of a well-established healthcare system, an increase in chronic diseases, and the involvement of key companies. For instance, in May 2019, AstraZeneca, a UK based company entered into a long-term collaboration with BenevolentAI to use artificial intelligence for the discovery and development of new treatment for IPF and Chronic Kidney Disease (CKD). Therefore, the market is expected to grow during the forecast period.

The market in Asia-Pacific is projected to have a steady growth rate during the forecast period owing to the increasing pool of patient population and increasing government initiatives for healthcare reforms.

The market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.

Global IPF Treatment Market, by Treatment

- Drug Class
  - MAPK Inhibitors
  - Tyrosine Kinase Inhibitors
  - Autotaxin Inhibitors
  - Others
- Oxygen Therapy
- Lung Transplant
- Others

Global IPF Treatment Market, by Region

- Americas
  - North America
    - US
    - Canada
Contents:

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations

Chapter 3. Research Methodology
  3.1 Overview
  3.2 Primary Research
  3.3 Secondary Research
  3.4 Market Size Estimation

Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
  4.3 Opportunities
  4.4 Challenges

Chapter 5. Market Factor Analysis
  5.1 Porter’s Five Forces Analysis
    5.1.1 Bargaining Power of Suppliers
    5.1.2 Bargaining Power of Buyers
    5.1.3 Threat of New Entrants
    5.1.4 Threat of Substitutes
    5.1.5 Intensity of Rivalry
    5.2 Value Chain Analysis

Chapter 6. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment
Chapter 6. Idiopathic Pulmonary Fibrosis (IPF) Market

6.1 Overview

6.2 Drug Class

6.2.1 MAPK Inhibitors
Market Estimates & Forecast, by Region, 2019–2025

6.2.2 Tyrosine Kinase Inhibitors
Market Estimates & Forecast, by Region, 2019–2025

6.2.3 Autotaxin Inhibitors
Market Estimates & Forecast, by Region, 2019–2025

6.2.4 Others
Market Estimates & Forecast, by Region, 2019–2025

6.3 Oxygen Therapy
Market Estimates & Forecast, by Region, 2019–2025

6.4 Lung Transplant
Market Estimates & Forecast, by Region, 2019–2025

6.5 Others
Market Estimates & Forecast, by Region, 2019–2025

Chapter 7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Region

7.1 Overview

7.2 Americas

7.2.1 North America

7.2.1.1 US
7.2.1.2 Canada

7.2.2 Latin America

7.3 Europe

7.3.1 Western Europe

7.3.1.1 Germany
7.3.1.2 France
7.3.1.3 Italy
7.3.1.4 Spain
7.3.1.5 UK
7.3.1.6 Rest of Western Europe

7.3.2 Eastern Europe

7.4 Asia-Pacific

7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia-Pacific

7.5 Middle East & Africa

7.5.1 Middle East
9.8.1 Overview
9.8.2 Product Type Overview
9.8.3 Financials
9.8.4 Key Developments
9.8.5 SWOT Analysis
9.9 Merck & Co., Inc.
9.9.1 Overview
9.9.2 Product Type Overview
9.9.3 Financials
9.9.4 Key Developments
9.9.5 SWOT Analysis
9.10 Novartis AG
9.10.1 Overview
9.10.2 Product Type Overview
9.10.3 Financials
9.10.4 Key Developments
9.10.5 SWOT Analysis
9.11 Prometic Life Sciences Inc.
9.11.1 Overview
9.11.2 Product Type Overview
9.11.3 Financials
9.11.4 Key Developments
9.11.5 SWOT Analysis
9.12 Others

Chapter 10 Appendix
10.1 References
10.2 Related Reports

LIST OF TABLES
Table 1 Global Idiopathic Pulmonary Fibrosis Treatment Market Synopsis, 2016–2025
Table 2 Global Idiopathic Pulmonary Fibrosis Treatment Market Estimates and Forecast, 2016–2025 (USD Million)
Table 3 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2016–2025 (USD Million)
Table 4 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Region, 2016–2025 (USD Million)
Table 5 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2016–2025 (USD Million)
Table 6 US: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2016–2025 (USD Million)
Table 7 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2016–2025 (USD Million)
Table 8 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2016–2025 (USD Million)
Table 9 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2016–2025 (USD Million)
Table 10 Western Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2016–2025 (USD Million)
Table 11 Eastern Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2016–2025 (USD Million)
Table 12 Asia-Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2016–2025 (USD Million)
Table 13 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2016–2025 (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Market Structure for Global Idiopathic Pulmonary Fibrosis Treatment Market
Figure 3 Market Dynamics for Global Idiopathic Pulmonary Fibrosis Treatment Market
Figure 4 Global Idiopathic Pulmonary Fibrosis Treatment Market Share, by Treatment, 2018 (%)
Figure 5 Global Idiopathic Pulmonary Fibrosis Treatment Market Share, by Region, 2018 (%)
Figure 6 North America: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Country, 2018 (%)
Figure 7 Europe: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Region, 2018 (%)
Figure 8 Western Europe: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Country, 2018 (%)
Figure 9 Asia-Pacific: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Country, 2018 (%)
Figure 10 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Country, 2018 (%)
Figure 11 Global Idiopathic Pulmonary Fibrosis Treatment Market: Company Share Analysis, 2018 (%)
Figure 12 Biogen: Key Financials
Figure 13 Biogen: Segmental Revenue
Figure 14 Biogen: Geographical Revenue
Figure 15 Boehringer Ingelheim GMBH: Key Financials
Figure 16 Boehringer Ingelheim GMBH: Segmental Revenue
Figure 17 Boehringer Ingelheim GMBH: Geographical Revenue
Figure 18 Bristol-Myers Squibb Company: Key Financials
Figure 19 Bristol-Myers Squibb Company: Segmental Revenue
Figure 20 Bristol-Myers Squibb Company: Geographical Revenue
Figure 21 Cipla: Key Financials
Figure 22 Cipla: Segmental Revenue
Figure 23 Cipla: Geographical Revenue
Figure 24 F. Hoffmann-La Roche AG: Key Financials
Figure 25 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 26 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 27 Fibrogen, Inc.: Key Financials
Figure 28 Fibrogen, Inc.: Segmental Revenue
Figure 29 Fibrogen, Inc.: Geographical Revenue
Figure 30 Galapagos NV: Key Financials
Figure 31 Galapagos NV: Segmental Revenue
Figure 32 Galapagos NV: Geographical Revenue
Figure 33 Medicinova, Inc.: Key Financials
Figure 34 Medicinova, Inc.: Segmental Revenue
Figure 35 Medicinova, Inc.: Geographical Revenue
Figure 36 Merck & Co., Inc.: Key Financials
Figure 37 Merck & Co., Inc.: Segmental Revenue
Figure 38 Merck & Co., Inc.: Geographical Revenue
Figure 39 Novartis AG: Key Financials
Figure 40 Novartis AG: Segmental Revenue
Figure 41 Novartis AG: Geographical Revenue
Figure 42 Prometic Life Sciences Inc.: Key Financials
Figure 43 Prometic Life Sciences Inc.: Segmental Revenue
Figure 44 Prometic Life Sciences Inc.: Geographical Revenue